COSCIENS Biopharma Inc.
CSCIF OTC
SEC CIK 1113423
Follow COSCIENS Biopharma
Weekly email: filings, results
Revenue, last quarter
$1.8M
−46.8% vs same quarter last year
Net income
−$2.2M
+67.6% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$1.5M
+51% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $7.5M | −$10.4M |
| FY24 | $9.6M | −$15.3M |
| FY23 | $7.1M | −$3.5M |
| FY22 | $14.6M | $3.4M |
| FY21 | $5.3M | −$8.4M |
| FY20 | $3.7M | −$5.1M |
| FY19 | $532K | −$6M |
| FY18 | $26.9M | $4.2M |
| FY17 | $923K | −$16.8M |
| FY16 | $911K | −$25M |
| FY15 | $545K | −$50.1M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 35.3% | −142.5% | −138.1% |
| FY24 | 49.3% | −190.7% | −159.7% |
| FY23 | 41.1% | −64.8% | −48.8% |
| FY22 | 58.7% | 29.6% | 23.7% |
| FY21 | 98.3% | −164.8% | −159.1% |
| FY20 | 36.6% | −156.2% | −140.1% |
| FY19 | 22.9% | −1925.2% | −1135.7% |
| FY18 | 92.2% | 36.6% | 15.6% |
| FY17 | 100% | −2499.9% | −1819.7% |
| FY16 | 100% | −3235.6% | −2739.7% |
| FY15 | - | −6400.7% | −9200.6% |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$9.2M |
| FY24 | −$15.7M |
| FY23 | −$3.3M |
| FY22 | $4.9M |
| FY21 | −$8.6M |
| FY20 | - |
| FY19 | - |
| FY18 | $6.8M |
| FY17 | −$22.9M |
| FY16 | −$29.1M |
| FY15 | −$33.9M |
| FY14 | - |
- COSCIENS Biopharma
- Materials median
Show the numbers
| Year | COSCIENS Biopharma | Materials median |
|---|---|---|
| FY25 | −138.1% | 2.3% |
| FY24 | −159.7% | 3.4% |
| FY23 | −48.8% | 4.4% |
| FY22 | 23.7% | 5.6% |
| FY21 | −159.1% | 6.4% |
| FY20 | −140.1% | 4.1% |
| FY19 | −1135.7% | 4.1% |
| FY18 | 15.6% | 5% |
| FY17 | −1819.7% | 4.9% |
| FY16 | −2739.7% | 4.8% |
| FY15 | −9200.6% | 3.3% |
| FY14 | - | 4.5% |